Anjon’s Novel  Cellular Protection Technology

  • Anjon technology uses a complex emollient that acts as an immune system stimulant and antioxidant specifically for skin cell wall protection.
  • Activated for the period of radiation exposure, using a deep tissue protection mechanism preventing skin  cell damage.
  • Anjon technology provides an open skin pore enhanced pass through environment reducing or eliminating  skin cell damage.
  • We expect our technology to significantly reduce the risk of skin cancer, it has been proven in testing to protect the skin from UVA and UVB radiation damage.


ARC™ for Radiation Dermatitis Treatment

  • ARC™ is an aqueous based topical cream for skin protection and  intervention of Radiation Dermatitis.
  • Formulated with a blend of a natural active ingredient and minerals that  act in tandem as catalysts for the protection of the DNA of individual  skin cells, preventing damage caused by radiation.
Indication(s) Radiation Dermatitis
Status & Timelines OTC Registered with 510k registration by end of 2016
Product USP(s) Ideal for all skin types. Has shown zero negative reactions


DermaPlus™ – A Multiplatform Topical Therapy


Diabetic Leg Ulcer Treatment

  • DermaPlus is a Hydro Gel Emollient for control of topical bacterial infections, infected wounds, burns and ulcerated sores.
  • DermaPlus is a multiplatform antibacterial product that is adaptable to many target treatments. Has been successfully used a as primary wound care product for animals for the past five years.
Indication(s) Topical bacterial infections including impetigo and resistant bacteria strains such as MRSA

  • Diabetic Skin Ulcers – often infected with antibiotic resistant bacteria strains
  • HSV 2
  • Acne
  • Shingles
  • Pressure sores
  • Burns  resulting from radiation therapies and other sources
Status & Timelines Finished 5 years of animal testing, early stage
Product USP(s) Ideal for all skin types. Has shown zero negative reactions

Acne Treatment


  • Patient previously treated with Accutane
  • DermaPlus applied twice a day for 7 days


The New Age of Disease Management

Antimicrobial Resistance Threatens Global Populations

World Health Organization (April 2015) – “Antimicrobial resistance for an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi is an increasingly serious threat to global public health that requires action across all government sectors and society.”


Antibacterial For the Treatment of Bacterial Infections

  • An antibacterial platform that has shown to effectively control infections including antibiotic resistant strains in animal testing.
  • Suited to either oral or intravenous application and is designed to stop bacterial infections.
  • A natural alternative substituting todays antibiotics
  • POC -The AB-100 will be registered as a new drug now entering PreIND (Investigative New Drug) testing.


Antiviral for the Treatment of Viral Diseases

  • An antiviral drug platform
  • Suited to either oral or intravenous application and is designed to stop the replication of the virus and allow natural death of the infected cells.
  • Offers an effective immunostimulant that encouragers increased t-cell production and an enhanced immune system response.

Cross platform technologies enhances market opportunities


Clinical Development Milestones